reports
- Sean Conroy
AlzeCure Pharma - Termination of coverage
Edison Investment Research is terminating coverage on Mercia Asset Management (MERC), Bloc Ventures (unlisted), YOC (YOC.DE), Genuit Group (GEN), AlzeCure Pharma (ALZCUR), abrdn Latin American Income Fund (ALAI), Magforce (MF6), OPG Power Ventures (OPG) and paragon (PGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
- Sean Conroy
AlzeCure Pharma - Progress on all fronts and evolving into Phase II
With fresh funding in place and the FDA’s response to a pre-IND application, AlzeCure is evolving into a Phase II company with the initiation of a Phase IIa study with ACD440, a topical TRPV1 antagonist, for pain. This will be the company’s most advanced clinical trial and a significant catalyst. Its most advanced asset in Alzheimer’s disease (AD), ACD856, a novel cognitive enhancer from its NeuroRestore platform, continues to advance through the multiple ascending dose (MAD) part of the Phase I...
AlzeCure Pharma (ALZCUR): Initiation - Well-balanced pipeline for Alzh...
Edison Investment Research Limited AlzeCure Pharma (ALZCUR): Initiation - Well-balanced pipeline for Alzheimer's and pain 24-March-2021 / 08:00 GMT/BST London, UK, 24 March 2021 AlzeCure Pharma (ALZCUR): Initiation - Well-balanced pipeline for Alzheimer's and pain AlzeCure is a pure play biotech focused on neurological disorders. The pipeline consists of three small-molecule platforms targeting Alzheimer's disease (AD) and pain. The NeuroRestore platform is focused on novel symptomatic treatment of AD (lead compound ACD856 is in Phase I), although there is a scientific ratio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.